AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Argent BioPharma Limited

0.115

-0.005-4.17%

Volume:6.30K

Turnover:724.00

Market Cap:8.30M

PE:-0.26

High:0.115

Open:0.115

Low:0.115

Close:0.120

Loading ...

Overview Company News Filings

Argent BioPharma Enters Germany - Europe's Largest Market

Argent BioPharma Amends Convertible Note Terms with US-Based Search Fund; Shares Fall 6%

MT Newswires Live

Argent BioPharma to Collaborate With AusCann on Cannabinoid-Based Pharmaceutical Development

MT Newswires Live

BRIEF-Argent Biopharma And Auscann Enters Strategic Heads Of Agreement

Argent Biopharma - Co, Auscann Entered Strategic Heads of Agreement to Accelerate Cannabinoid-Based Pharmaceutical Development

THOMSON REUTERS

Argent Biopharma - Auscann Will License Argent Biopharma's Cannepil Cmc and Dossier for Non-Epilepsy Related Pharmaceutical Programs

THOMSON REUTERS

Argent BioPharma Signs Term Sheet with Medical Cannabis Research Company; Shares Down 5%

MT Newswires Live

BRIEF-Argent Biopharma Enters Collaboration Agreement For Argent EU GMP Facility In Malta

Argent Biopharma Ltd - Strategic Collaboration Agreement for Argent EU Gmp Facility in Malta

THOMSON REUTERS

Argent Biopharma - David Trading Granted Exclusive, Irrevocable Option to Acquire 100% of Facility Company's Shares

THOMSON REUTERS

ASX Runners of the Week: Whitehawk, OzAurum, Argent Biopharma & Galan

The West Australian

Argent BioPharma gains approval for prescription sales of CannEpil epilepsy treatment in Germany

BRIEF-Argent Biopharma Says Cannepil Receives Approval For Prescription In Germany

ASX Small-Cap Stocks to Watch

MT Newswires Live

Argent Biopharma - Cannepil Receives Approval for Prescription in Germany

THOMSON REUTERS

BRIEF-Argent BioPharma Reports Agreement For Malta Manufacturing Facility

Exclusive Agreement for Malta Manufacturing Facility-RGT.ax

THOMSON REUTERS

Argent Biopharma Ltd - Under Term Sheet, Argent Biopharma Must Receive a Minimum Consideration of US$1 Mln

THOMSON REUTERS

Argent Biopharma Ltd - Eccpharm to Provide Gmp Manufacturing for Argent Biopharma

THOMSON REUTERS

BRIEF-Argent BioPharma Posts HY Net Loss Attributable A$12.2 Million

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/RGT.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RGT.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RGT.AU\",,,,,undefined,":{"symbol":"RGT.AU","market":"AU","secType":"STK","nameCN":"Argent BioPharma Limited","latestPrice":0.115,"timestamp":1746684005355,"preClose":0.12,"halted":0,"volume":6295,"delay":0,"nameEN":"Argent BioPharma Limited","floatShares":14793190,"shares":72183153,"eps":-0.44518,"marketStatus":"Closed","change":-0.005,"latestTime":"05-08 16:00:05 AEST","open":0.115,"high":0.115,"low":0.115,"amount":724,"amplitude":0,"askPrice":0.12,"askSize":2151,"bidPrice":0.115,"bidSize":4347,"shortable":3,"etf":0,"ttmEps":-0.44518,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1746748800000},"marketStatusCode":5,"adr":0,"exchange":"ASX","adjPreClose":0.12,"openAndCloseTimeList":[[1746662400000,1746684000000]],"volumeRatio":0.214279,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RGT.AU\",,,,,undefined,":{"symbol":"RGT.AU","floatShares":14793190,"roa":"-121.60%","roe":"--","lyrEps":-0.47364,"volumeRatio":0.214279,"shares":72183153,"dividePrice":0,"high":0.115,"amplitude":0,"preClose":0.12,"low":0.115,"week52Low":0.115,"pbRate":"-0.76","psRate":"28.06","week52High":0.57,"institutionHeld":0,"latestPrice":0.115,"committee":0.33795,"eps":-0.44518,"divideRate":0,"volume":6295,"delay":0,"ttmEps":-0.44518,"open":0.115,"prevYearClose":0.17,"prevWeekClose":0.13,"prevMonthClose":0.13,"prevQuarterClose":0.17,"fiveDayClose":0.125,"twentyDayClose":0.19,"sixtyDayClose":0.13},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RGT.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2529698743","title":"Argent BioPharma Enters Germany - Europe's Largest Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2529698743","media":"PR Newswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529698743?lang=en_us&edition=fundamental","pubTime":"2025-04-24 07:00","pubTimestamp":1745449200,"startTime":"0","endTime":"0","summary":"Strategic Expansion Paired with Over $1M in Annual Cost Savings from Operational Restructuring. PERTH, Australia, April 23, 2025 /PRNewswire/ --Argent BioPharma Ltd.  , a clinical-stage biopharmaceutical company specializing in neuroimmune therapies, is pleased to announce its official entry into the German pharmaceutical market with the receipt of initial purchase orders for CannEpil and CogniCann, following recent regulatory approval. Germany, as the largest healthcare market in Europe, represents a significant commercial milestone and a strategic beachhead for Argent's broader European expansion.These achievements reflect Argent BioPharma's broader transformation strategy—centered on fully proprietary, neuroimmune drug development, in-house innovation, and sustainable global scalability. The Company remains focused on advancing its therapeutic pipeline while deepening market penetration across high-value regions.About Argent BioPharmaArgent BioPharma Ltd.  develops proprietary thera","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance_au","url":"https://finance.yahoo.com/news/argent-biopharma-enters-germany-europes-230000750.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/argent-biopharma-enters-germany-europes-230000750.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK4135","NIM","NIM.AU","BK7096","RGT.AU","CNS","BK7095"],"gpt_icon":0},{"id":"2529546944","title":"Argent BioPharma Amends Convertible Note Terms with US-Based Search Fund; Shares Fall 6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2529546944","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529546944?lang=en_us&edition=fundamental","pubTime":"2025-04-23 14:02","pubTimestamp":1745388168,"startTime":"0","endTime":"0","summary":"Argent BioPharma  has executed a deed of variation with Mercer Street Global Opportunity Fund to amend the terms of its 2020 convertible securities agreement, according to a Wednesday filing with the Australian bourse.The adjustment involves refinancing 300,000 convertible notes, worth AU$1.1 million, reducing the minimum conversion price to not less than AU$0.11 from not less than AU$10, the filing said.The company also plans to negotiate further amendments to the remaining 2020 and 2022 convertible note facilities, the filing added.Shares of the company fell 6% in recent Wednesday trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","RGT.AU"],"gpt_icon":0},{"id":"2527848847","title":"Argent BioPharma to Collaborate With AusCann on Cannabinoid-Based Pharmaceutical Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2527848847","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527848847?lang=en_us&edition=fundamental","pubTime":"2025-04-15 11:16","pubTimestamp":1744687000,"startTime":"0","endTime":"0","summary":"Argent BioPharma  and AusCann Group Holdings signed a strategic heads of agreement to advance cannabinoid-based pharmaceutical development through the exchange of proprietary datasets and regulatory expertise, according to a Tuesday Australian bourse filing.AusCann will license Argent BioPharma's CannEpil CMC and Dossier specifically for non-epilepsy-related pharmaceutical programs.The companies will also gain access to AusCann's proprietary self-emulsifying hard-shell capsule formulation, Neuvis, including access to pharmacokinetic and pharmacodynamic data.The firms will also establish a joint steering committee to coordinate research and development efforts as well as optimize regulatory strategies.The agreement also includes a deferred licensing fee structure, with royalties on pharmaceutical products developed using jointly leveraged data, research and development, or assets.Financial terms were not disclosed.Argent BioPharma's shares were down almost 3% in recent Tuesday trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RGT.AU","BK7096"],"gpt_icon":0},{"id":"2527177694","title":"BRIEF-Argent Biopharma And Auscann Enters Strategic Heads Of Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2527177694","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527177694?lang=en_us&edition=fundamental","pubTime":"2025-04-15 09:29","pubTimestamp":1744680595,"startTime":"0","endTime":"0","summary":"BRIEF-Argent Biopharma And Auscann Enters Strategic Heads Of AgreementApril 15  - Argent BioPharma Ltd RGT.AX:CO, AUSCANN ENTERED STRATEGIC HEADS OF AGREEMENT TO ACCELERATE CANNABINOID-BASED PHARMACEUTICAL DEVELOPMENTAUSCANN WILL LICENSE ARGENT BIOPHARMA'S CANNEPIL CMC AND DOSSIER FOR NON-EPILEPSY RELATED PHARMACEUTICAL PROGRAMSFurther company coverage: RGT.AX ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250415:nFWN3QS1YZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RGT.AU","BK7096"],"gpt_icon":0},{"id":"2527812173","title":"Argent Biopharma - Co, Auscann Entered Strategic Heads of Agreement to Accelerate Cannabinoid-Based Pharmaceutical Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2527812173","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527812173?lang=en_us&edition=fundamental","pubTime":"2025-04-15 07:08","pubTimestamp":1744672135,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250414:nFWN3QS1YZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RGT.AU","BK7096"],"gpt_icon":0},{"id":"2527121787","title":"Argent Biopharma - Auscann Will License Argent Biopharma's Cannepil Cmc and Dossier for Non-Epilepsy Related Pharmaceutical Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2527121787","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527121787?lang=en_us&edition=fundamental","pubTime":"2025-04-15 07:08","pubTimestamp":1744672135,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250414:nFWN3QS1YZ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","RGT.AU"],"gpt_icon":0},{"id":"2526379050","title":"Argent BioPharma Signs Term Sheet with Medical Cannabis Research Company; Shares Down 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2526379050","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526379050?lang=en_us&edition=fundamental","pubTime":"2025-04-10 10:45","pubTimestamp":1744253159,"startTime":"0","endTime":"0","summary":"Argent BioPharma  signed a binding term sheet with David Trading to operate its facility in Malta for a 49-year term, according to a Wednesday filing with the Australian bourse.The plant, which specializes in liquid dose form production for anti-inflammatory treatment CimetrA, can produce thousands of units per day, the filing said.David Trading will bear all financial and operational responsibilities for the facility, including all debts and liabilities incurred from the signing date forward, per the filing.Argent BioPharma shares were down 5% in afternoon trade Thursday.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RGT.AU","BK7096"],"gpt_icon":0},{"id":"2526824441","title":"BRIEF-Argent Biopharma Enters Collaboration Agreement For Argent EU GMP Facility In Malta","url":"https://stock-news.laohu8.com/highlight/detail?id=2526824441","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526824441?lang=en_us&edition=fundamental","pubTime":"2025-04-09 07:12","pubTimestamp":1744153945,"startTime":"0","endTime":"0","summary":"BRIEF-Argent Biopharma Enters Collaboration Agreement For Argent EU GMP Facility In MaltaApril 9  - Argent BioPharma Ltd RGT.AX:STRATEGIC COLLABORATION AGREEMENT FOR ARGENT EU GMP FACILITY IN MALTASTRATEGIC COLLABORATION GRANTING DAVID TRADING EXCLUSIVE RIGHTS TO OPERATE RGT'S FACILITY IN MALTADAVID TRADING GRANTED EXCLUSIVE, IRREVOCABLE OPTION TO ACQUIRE 100% OF FACILITY COMPANY'S SHARESFurther company coverage: RGT.AX ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250408:nFWN3QM1YV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RGT.AU","BK7096"],"gpt_icon":0},{"id":"2526244948","title":"Argent Biopharma Ltd - Strategic Collaboration Agreement for Argent EU Gmp Facility in Malta","url":"https://stock-news.laohu8.com/highlight/detail?id=2526244948","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526244948?lang=en_us&edition=fundamental","pubTime":"2025-04-09 07:10","pubTimestamp":1744153816,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250408:nFWN3QM1YV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RGT.AU","BK7096"],"gpt_icon":0},{"id":"2526244118","title":"Argent Biopharma - David Trading Granted Exclusive, Irrevocable Option to Acquire 100% of Facility Company's Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2526244118","media":"THOMSON REUTERS","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526244118?lang=en_us&edition=fundamental","pubTime":"2025-04-09 07:10","pubTimestamp":1744153816,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250408:nFWN3QM1YV:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RGT.AU","BK7096"],"gpt_icon":0},{"id":"2524560220","title":"ASX Runners of the Week: Whitehawk, OzAurum, Argent Biopharma & Galan","url":"https://stock-news.laohu8.com/highlight/detail?id=2524560220","media":"The West Australian","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524560220?lang=en_us&edition=fundamental","pubTime":"2025-04-04 06:02","pubTimestamp":1743717723,"startTime":"0","endTime":"0","summary":"This week’s Bulls N’ Bears ASX Runner of the Week is… Whitehawk Ltd after the company bagged a major spot as the core cyber partner in a massive US$920M (A$1474M) US government contract.","market":"nz","thumbnail":"https://images.thewest.com.au/publication/C-18264459/f3ba145e5bde0aa97d4b38a2ae55d7e52f82c4d9.jpg","type":0,"news_type":0,"thumbnails":["https://images.thewest.com.au/publication/C-18264459/f3ba145e5bde0aa97d4b38a2ae55d7e52f82c4d9.jpg"],"rights":{"source":"thewest_stock","url":"https://thewest.com.au/business/bulls-n-bears/asx-runners-of-the-week-whitehawk-ozaurum-argent-biopharma-galan-c-18264459","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://thewest.com.au/business/bulls-n-bears/asx-runners-of-the-week-whitehawk-ozaurum-argent-biopharma-galan-c-18264459","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"thewest_stock","symbols":["XKO.AU","BK7104","WHK.AU","XAO.AU","BK7049","BK7096","BK7024","BK7095","XJO.AU","LCE.AU","BK7507","GLN.AU","PLS.AU","OZM.AU","RGT.AU","BK7504","BK7105"],"gpt_icon":0},{"id":"2524408705","title":"Argent BioPharma gains approval for prescription sales of CannEpil epilepsy treatment in Germany","url":"https://stock-news.laohu8.com/highlight/detail?id=2524408705","media":"Small Caps","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524408705?lang=en_us&edition=fundamental","pubTime":"2025-04-03 12:21","pubTimestamp":1743654102,"startTime":"0","endTime":"0","summary":"Argent BioPharma’s  flagship CannEpil cannabinoid-based therapy for the treatment of refractory  epilepsy has been approved for prescription in Germany under a special access scheme.The approval means that doctors can now prescribe the drug to eligible patients, who may also qualify for health insurance coverage depending on the doctor’s recommendation and case assessment.It represents a significant step in Argent’s European expansion strategy and strengthens its presence in the German market, a key pharmaceutical hub.Argent plans to work towards raising CannEpil’s German profile through education programs for medical professionals and the expansion of distribution channels through key regional partners.The company will also monitor market updates and patient outcomes to support the product’s ongoing research and development.Argent expects the prescription approval to pave the way for broader penetration into other markets within the European Union that have similar regulatory pathways","market":"us","thumbnail":"https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2025/04/Argent-Biopharma-ASX-RGT-CannEpil-Approval-Prescription-Germany.jpg","type":0,"news_type":0,"thumbnails":["https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2025/04/Argent-Biopharma-ASX-RGT-CannEpil-Approval-Prescription-Germany.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://smallcaps.com.au/argent-biopharma-approval-prescription-sales-cannepil-epilepsy-germany/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"smallcap_stock","symbols":["BK7096","RGT.AU"],"gpt_icon":0},{"id":"2524228194","title":"BRIEF-Argent Biopharma Says Cannepil Receives Approval For Prescription In Germany","url":"https://stock-news.laohu8.com/highlight/detail?id=2524228194","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524228194?lang=en_us&edition=fundamental","pubTime":"2025-04-03 09:06","pubTimestamp":1743642369,"startTime":"0","endTime":"0","summary":"BRIEF-Argent Biopharma Says Cannepil Receives Approval For Prescription In GermanyApril 3 (Reuters) - Argent BioPharma Ltd RGT.AX:CANNEPIL RECEIVES APPROVAL FOR PRESCRIPTION IN GERMANYSource text: ID:nASX9H5bTJFurther company coverage: RGT.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250403:nFWN3QG0TZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","RGT.AU"],"gpt_icon":0},{"id":"2524450423","title":"ASX Small-Cap Stocks to Watch","url":"https://stock-news.laohu8.com/highlight/detail?id=2524450423","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524450423?lang=en_us&edition=fundamental","pubTime":"2025-04-03 07:41","pubTimestamp":1743637281,"startTime":"0","endTime":"0","summary":"Investors are likely to keep an eye on the following small-cap stocks listed on the Australian Securities Exchange.Reward Minerals Reward Minerals subsidiary Holocene applied for a new exploration license prospective for gypsum. The application area includes historic mining tenement areas where auger drilling, costeaning and test pitting by multiple explorers defined \"substantial\" gypsum deposits.Western Mines Group Western Mines Group completed the first mineral resource estimate for the shallow disseminated nickel sulfide mineralization at the Mulga Tank project in Western Australia.Miramar Resources Miramar Resources secured a drill rig for gold exploration expected to start next week at the Gidji joint venture project in Western Australia.Gold Mountain Gold Mountain launched a one-for-three pro rata accelerated renounceable entitlement offer, offering retail rights trading of new shares at a price of AU$0.002 apiece. The offer aims to raise up to AU$3.1 million, with one attaching ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["GMN.AU","RGT.AU","M2R.AU","RWD.AU","BK7095","WMG.AU","BK7020","BK7104","BK7096"],"gpt_icon":0},{"id":"2524544250","title":"Argent Biopharma - Cannepil Receives Approval for Prescription in Germany","url":"https://stock-news.laohu8.com/highlight/detail?id=2524544250","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524544250?lang=en_us&edition=fundamental","pubTime":"2025-04-03 05:50","pubTimestamp":1743630608,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250402:nFWN3QG0TZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","RGT.AU"],"gpt_icon":0},{"id":"2518107088","title":"BRIEF-Argent BioPharma Reports Agreement For Malta Manufacturing Facility","url":"https://stock-news.laohu8.com/highlight/detail?id=2518107088","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518107088?lang=en_us&edition=fundamental","pubTime":"2025-03-12 09:14","pubTimestamp":1741742075,"startTime":"0","endTime":"0","summary":"BRIEF-Argent BioPharma Reports Agreement For Malta Manufacturing FacilityMarch 12  - Argent BioPharma RGT.AX:EXCLUSIVE AGREEMENT FOR MALTA MANUFACTURING FACILITY-RGT.AXUNDER TERM SHEET, ARGENT BIOPHARMA MUST RECEIVE A MINIMUM CONSIDERATION OF US$1 MILLIONUNDER TERM SHEET, ARGENT BIOPHARMA MUST RECEIVE A MINIMUM CONSIDERATION OF US$1 MILLIONFurther company coverage: RGT.AX ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250312:nFWN3PU14O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RGT.AU","BK7096"],"gpt_icon":0},{"id":"2518057787","title":"Exclusive Agreement for Malta Manufacturing Facility-RGT.ax","url":"https://stock-news.laohu8.com/highlight/detail?id=2518057787","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518057787?lang=en_us&edition=fundamental","pubTime":"2025-03-12 06:49","pubTimestamp":1741733351,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250311:nFWN3PU14O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RGT.AU","BK7096"],"gpt_icon":0},{"id":"2518057747","title":"Argent Biopharma Ltd - Under Term Sheet, Argent Biopharma Must Receive a Minimum Consideration of US$1 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2518057747","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518057747?lang=en_us&edition=fundamental","pubTime":"2025-03-12 06:49","pubTimestamp":1741733351,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250311:nFWN3PU14O:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RGT.AU","BK7096"],"gpt_icon":0},{"id":"2517987749","title":"Argent Biopharma Ltd - Eccpharm to Provide Gmp Manufacturing for Argent Biopharma","url":"https://stock-news.laohu8.com/highlight/detail?id=2517987749","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517987749?lang=en_us&edition=fundamental","pubTime":"2025-03-05 06:54","pubTimestamp":1741128867,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nFWN3PN0OF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RGT.AU","BK7096"],"gpt_icon":0},{"id":"2514314680","title":"BRIEF-Argent BioPharma Posts HY Net Loss Attributable A$12.2 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2514314680","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514314680?lang=en_us&edition=fundamental","pubTime":"2025-02-28 16:19","pubTimestamp":1740730763,"startTime":"0","endTime":"0","summary":"BRIEF-Argent BioPharma Posts HY Net Loss Attributable A$12.2 MillionFeb 28 (Reuters) - Argent BioPharma Ltd RGT.AX:HY NET LOSS ATTRIBUTABLE A$12.2 MILLIONSource text: ID:nASX2LZQkCFurther company coverage: RGT.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250228:nFWN3PI2I6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RGT.AU","BK7096"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":39,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RGT.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2024-09-23","symbol":"RGT.AU","reason":null,"defaultRemindTime":1727049600000,"announcedDate":"2024-08-15","type":"delisting","dateTimestamp":1727013600000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RGT.AU\",market:\"AU\",,,undefined,":[]}}